Anthrax immune globulin intravenous (Human, Cangene Corporation)

N/A

Report date: 2022/04/06 20:00:35

Base Information

Drug NameAnthrax immune globulin intravenous (Human, Cangene Corporation)
Drug Alias Name炭疽免疫球蛋白 - Emergent BioSolutions/CangeneAIGIVAnthrax immune globulinAnthrax immune globulin - Emergent BioSolutions (Cangene)Anthrax immune globulin intravenous +[7] 
ClassificationBiologics > Blood componentsBiologics > Protein drugs > Immunoglobulin
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsInhalational anthraxAnthrax
Global Approved IndicationsInhalational anthraxAnthrax
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/03/24
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesCangene Corp
China Registration ClassN/A

Develop Information

Active CompaniesInstitute of Bioengineering Academy of Military Medical Sciences Chinese People's Liberation ArmyGuizhou Taibang Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsInhalational anthraxAnthrax
Inactive IndicationsN/A

Other Information

ATC CodeJ06BB19
Related LinksN/A